首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
首頁 > 市場調查報告書 > 製藥 > 全球新興藥品市場
產業/市場分類
製藥 (4816)
肥胖症治療 (44)
非專利藥 (129)
疫苗 (181)
神經疾病 (172)
骨頭疾病治療 (37)
動物用醫藥 (17)
處方藥 (156)
規章 (126)
感染疾病 (346)
精神病 (84)
製藥企業 (524)
糖尿病 (191)
癌症 (909)
藥物開發 (1449)
DDS (182)
OTC 非處方藥 (150)
市場調查報告書

全球新興藥品市場

Emerging Pharmaceutical Markets Globally

出版商 RNCOS E-Services Pvt. Ltd.
出版日期 2009年12月 商品編碼 105823
內容資訊 英文 130 Pages
價格
本報告書已不再販售

本報告已在2012年03月01日停止出版。

更改為出版

全球新興醫藥品市場
Emerging Pharmaceutical Markets Globally
出版日期 : 2011年11月
商品編碼: 223492

簡介

新興國家的藥品市場已經以凌駕全球市場的程度發展起來了。其背景為，急速劇烈的經濟成長，個人所得増加，生活習慣病的増加，低成本等等因素使其向上提升。2008年中新興7國(巴西、俄國、中國、印度、土耳其、墨西哥、印尼)的藥品市場預計將達到960億美金。

本報告書中提供了新興國醫藥市場的人口動態，巨觀經濟指標，疾病資料，主要促進與阻礙因子的概括情報，更有市場戰略，機會的評價統整，概述如下。

第1章　分析師的見解

第2章　世界市場

  • 市場規模
  • 成熟市場：G7
  • 新興市場：E7
  • 堅強地成長的E7

第3章　E7藥品市場發展的理由

  • 經濟成長
  • 所得水準
  • 人工基盤
  • 生活習慣相關疾病的患病率
  • 醫學・流通基礎架構
  • 健康保險

第4章　産業銷售成績

  • 巴西(過去、現在・將來的流程)
    • 巨觀的經濟指標
    • 人口資料
    • 疾病資料
    • 醫療支出以及融資
    • 藥品市場
    • 輸入・輸出
    • 副廠藥品
    • 治療分類
    • 主要企業
  • 俄國(過去、現在・將來的流程)
    • 巨觀的經濟指標
    • 人口資料
    • 疾病資料
    • 醫療支出以及融資
    • 藥品市場
    • 輸入
    • 品牌藥品・副廠藥品
    • 主要企業
  • 印度(過去、現在・將來的流程)
    • 巨觀的經濟指標
    • 人口資料
    • 疾病資料
    • 醫療支出以及融資
    • 藥品市場
    • 輸入・輸出
    • 品牌藥品・副廠藥品
    • 治療分類
    • 主要企業
  • 中國(過去、現在・將來的流程)
    • 巨觀的經濟指標
    • 人口資料
    • 疾病資料
    • 醫療支出以及融資
    • 藥品市場
    • 輸入・輸出
    • 品牌藥品・副廠藥品
    • 治療分類
    • 主要企業
  • 土耳其(過去、現在・將來的流程)
    • 巨觀的經濟指標
    • 人口資料
    • 疾病資料
    • 醫療支出以及融資
    • 藥品市場
    • 輸入・輸出
    • 品牌藥品・副廠藥品
    • 治療分類
    • 主要企業
  • 墨西哥(過去、現在・將來的流程)
    • 巨觀的經濟指標
    • 人口資料
    • 疾病資料
    • 醫療支出以及融資
    • 藥品市場
    • 輸入・輸出
    • 品牌藥品・副廠藥品
    • 治療分類
    • 主要企業
  • 印尼(過去、現在・將來的流程)
    • 巨觀的經濟指標
    • 人口資料
    • 疾病資料
    • 醫療支出以及融資
    • 藥品市場
    • 輸入・輸出
    • 品牌藥品・副廠藥品
    • 主要企業

第5章　機會

  • 慢性疾病
  • 藥品外包市場
  • 疫苗市場
  • 醫療機器市場

第6章　抑制力

  • 仿造藥品
  • 專利保護
  • 傳統藥品

第7章　主要企業

  • GlaxoSmithKline
  • Sanofi-Aventis
  • Pfizer Inc.
  • Novartis
  • AstraZeneca

圖表

目錄

Abstract

The growth in pharma markets in emerging countries has outpaced the overall growth of the global pharma market. The growth in these markets is being driven by rapidly growing economies of these countries, increasing per capita income, increasing prevalence of lifestyle diseases, and low-cost factors. In 2008, pharma market in E7 countries (Brazil, Russia, China, India, Turkey, Mexico and Indonesia) was estimated at around US$ 96 Billion, and it is expected that high growth in these markets will help these countries increase their share in global pharma market.

According to our new research study on the sector titled “Emerging Pharmaceutical Markets Globally”, the pharmaceutical market in the abovementioned emerging countries is projected to grow at a CAGR of around 14.7% during 2009-2012. Currently, these markets are characterized by rapid urbanization, which has led to the growth in prevalence of lifestyle diseases.

Our report has found that China has the largest pharma market out of these seven countries, followed by Brazil, Mexico and India. However, the maximum growth in future is expected to be in Russia and China due to strong government support. Besides, we have identified that most of the E7 pharmaceutical markets are still dominated by acute therapies, but the growth rate of chronic therapies far exceeds that of acute therapies. Thus, the therapy mix of the market in the next few years will be much different from what it is today.

The research study provides extensive and coherent information about pharma markets in emerging countries. It highlights several emerging opportunities growing in line with development of pharma markets in E7 countries. The research study gives detailed statistical and analytical review on demographics, macroeconomic indicators, disease profile, key drivers and restraints. It contains all the key details that will help clients to draw up market strategies and assess opportunity areas for their success in these emerging pharma markets.

Table of Contents

1. Analyst View

2. Global Pharmaceutical Market

  • 2.1 Market Size
  • 2.2 Mature Markets - G7 Countries
  • 2.3 Emerging Markets - E7 Countries
  • 2.4 E7 Countries to Grow Strongly

3. Why E7 Pharmaceutical Market?

  • 3.1 Economic Growth
  • 3.2 Income Level
  • 3.3 Population Base
  • 3.4 Prevalence of Lifestyle-related Diseases
  • 3.5 Medical & Distribution Infrastructure
  • 3.6 Health Insurance

4. Industry Performance

  • 4.1 Brazil (Past, Present & Future Scenario)
    • 4.1.1 Macroeconomic Indicators
    • 4.1.2 Population Profile
    • 4.1.3 Disease Profile
    • 4.1.4 Healthcare Spending & Financing
    • 4.1.5 Pharmaceutical Market
    • 4.1.6 Import & Export
    • 4.1.7 Generic Drugs
    • 4.1.8 Therapy Areas
    • 4.1.9 Key Players
  • 4.2 Russia (Past, Present & Future Scenario)
    • 4.2.1 Macroeconomic Indicators
    • 4.2.2 Population Profile
    • 4.2.3 Disease Profile
    • 4.2.4 Healthcare Spending & Financing
    • 4.2.5 Pharmaceutical Market
    • 4.2.6 Import
    • 4.2.7 Branded & Generic Drugs
    • 4.2.8 Key Players
  • 4.3 India (Past, Present & Future Scenario)
    • 4.3.1 Macroeconomic Indicators
    • 4.3.2 Population Profile
    • 4.3.3 Disease Profile
    • 4.3.4 Healthcare Spending & Financing
    • 4.3.5 Pharmaceutical Market
    • 4.3.6 Import & Export
    • 4.3.7 Branded & Generic Drugs
    • 4.3.8 Therapy Areas
    • 4.3.9 Key Players
  • 4.4 China (Past, Present & Future Scenario)
    • 4.4.1 Macroeconomic Indicators
    • 4.4.2 Population Profile
    • 4.4.3 Disease Profile
    • 4.4.4 Healthcare Spending & Financing
    • 4.4.5 Pharmaceutical Market
    • 4.4.6 Import & Export
    • 4.4.7 Branded & Generic Drugs
    • 4.4.8 Therapy Areas
    • 4.4.9 Key Players
  • 4.5 Turkey (Past, Present & Future Scenario)
    • 4.5.1 Macroeconomic Indicators
    • 4.5.2 Population Profile
    • 4.5.3 Disease Profile
    • 4.5.4 Healthcare Spending & Financing
    • 4.5.5 Pharmaceutical Market
    • 4.5.6 Import & Export
    • 4.5.7 Branded & Generic Drugs
    • 4.5.8 Therapy Areas
    • 4.5.9 Key Players
  • 4.6 Mexico (Past, Present & Future Scenario)
    • 4.6.1 Macroeconomic Indicators
    • 4.6.2 Population Profile
    • 4.6.3 Disease Profile
    • 4.6.4 Healthcare Spending & Financing
    • 4.6.5 Pharmaceutical Market
    • 4.6.6 Import & Export
    • 4.6.7 Branded & Generic Drugs
    • 4.6.8 Therapy Areas
    • 4.6.9 Key Players
  • 4.7 Indonesia (Past, Present & Future Scenario)
    • 4.7.1 Macroeconomic Indicators
    • 4.7.2 Population Profile
    • 4.7.3 Disease Profile
    • 4.7.4 Healthcare Spending & Financing
    • 4.7.5 Pharmaceutical Market
    • 4.7.6 Import & Export
    • 4.7.7 Branded & Generic Drugs
    • 4.7.8 Key Players

5. Opportunities

  • 5.1 Chronic Diseases
  • 5.2 Pharma Outsourcing Market
  • 5.3 Vaccine Market
  • 5.4 Medical Devices Market

6. Restraining Forces

  • 6.1 Counterfeit Drugs
  • 6.2 Patent Protection
  • 6.3 Traditional Medicines

7. Key Players

  • 7.1 GlaxoSmithKline
  • 7.2 Sanofi-Aventis
  • 7.3 Pfizer Inc.
  • 7.4 Novartis
  • 7.5 AstraZeneca

List of Figures:

  • Figure 2-1: Global - Pharmaceutical Market (Billion US$), 2005-2008
  • Figure 2-2: Global - Forecast for Pharmaceutical Market (Billion US$), 2009-2012
  • Figure 2-3: G7 Countries - Pharmaceutical Market (Billion US$), 2008
  • Figure 2-4: G7 Countries - Forecast for Pharmaceutical Market (Billion US$), 2012
  • Figure 2-5: G7 Countries - Forecast for Growth of Pharmaceutical Market (%), 2009 to 2012
  • Figure 2-6: E7 Countries - Pharmaceutical Market (Billion US$), 2008
  • Figure 2-7: E7 Countries - Forecast for Pharmaceutical Market (Billion US$), 2012
  • Figure 2-8: E7 Countries - Forecast for Growth of Pharmaceutical Market (%), 2009 to 2012
  • Figure 2-9: Global - Share of E7 & G7 Countries in Pharmaceutical Market (2008 & 2012)
  • Figure 3-1: G7 Countries - Real GDP (Trillion US$), 2004 & 2012
  • Figure 3-2: E7 Countries - Real GDP (Trillion US$), 2004 & 2012
  • Figure 3-3: Global - Share of E7 & G7 Countries in Population (2007 & 2012)
  • Figure 3-4: Relative Per Capita Spending on Drugs by Age Group
  • Figure 4-1: Brazil - Nominal GDP (Billion US$), 2007-2012
  • Figure 4-2: Brazil - Consumer Price Index (%), 2007-2012
  • Figure 4-3: Brazil - Currency Exchange Rate (From US$ to BRL), 2007-2012
  • Figure 4-4: Brazil - Foreign Direct Investment (Billion US$), 2005-2008
  • Figure 4-5: Brazil - Population (Million), 2006-2012
  • Figure 4-6: Brazil - Breakup of Population by Age Group (%), 2006-2012
  • Figure 4-7: Brazil - Population in the Age Group of 65 Years & Above (Million), 2006-2012
  • Figure 4-8: Brazil - Number of Deaths due to Leading Causes (‘000)
  • Figure 4-9: Brazil - Breakup of Deaths by Various Causes (%), 2008
  • Figure 4-10: Brazil - Per Head Healthcare Spending (US$), 2006-2012
  • Figure 4-11: Brazil - Breakup of Healthcare Payment by Source (%), 2008
  • Figure 4-12: Brazil - Pharmaceutical Market (Billion US$), 2007-2012
  • Figure 4-13: Brazil - Pharmaceutical Imports (Billion US$), 2005-2008
  • Figure 4-14: Brazil - Pharmaceutical Exports (Million US$), 2005-2008
  • Figure 4-15: Brazil - Generic Drugs Market (Million US$), 2006-2012
  • Figure 4-16: Brazil - Share of Generic Drugs in Pharmaceutical Market (2008 & 2012)
  • Figure 4-17: Brazil - Pharmaceutical Market by Segment (%), 2008
  • Figure 4-18: Russia - Nominal GDP (Billion US$), 2007-2012
  • Figure 4-19: Russia - Consumer Price Index (%), 2007-2012
  • Figure 4-20: Russia - Foreign Direct Investment (Billion US$), 2005-2008
  • Figure 4-21: Russia - Population (Million), 2007-2012
  • Figure 4-22: Russia - Breakup of Population by Age Group (%), 2007-2012
  • Figure 4-23: Russia - Population in the Age Group of 65 Years & Above (Million), 2007-2012
  • Figure 4-24: Russia - Number of Deaths due to Leading Causes (‘000)
  • Figure 4-25: Russia - Breakup of Deaths by Various Causes (%), 2008
  • Figure 4-26: Russia - Per Head Healthcare Spending (US$), 2006-2012
  • Figure 4-27: Russia - Breakup of Healthcare Payment by Source (%), 2008
  • Figure 4-28: Russia - Pharmaceutical Market (Billion Rubles), 2007-2012
  • Figure 4-29: Russia - Pharmaceutical Imports (Billion Rubles), 2007 & 2008
  • Figure 4-30: Russia - Share of Branded & Generic Drugs in Pharmaceutical Market (2008)
  • Figure 4-31: India - Nominal GDP (Billion US$), 2007-2012
  • Figure 4-32: India - Consumer Price Index (%), 2007-2012
  • Figure 4-33: India - Foreign Direct Investment (Billion US$), 2006-07 to 2008-09
  • Figure 4-34: India - Foreign Direct Investment in Pharmaceutical Market (Million US$), 2006-07 to 2008-09
  • Figure 4-35: India - Population (Million), 2006-2012
  • Figure 4-36: India - Breakup of Population by Age Group (%), 2006-2012
  • Figure 4-37: India - Population in the Age Group of 65 Years & Above (Million), 2006-2012
  • Figure 4-38: India - Number of Deaths due to Leading Causes (‘000)
  • Figure 4-39: India - Breakup of Deaths by Various Causes (%), 2008
  • Figure 4-40: India - Per Head Healthcare Spending (US$), 2006-2012
  • Figure 4-41: India - Breakup of Healthcare Payment by Source (%), 2006
  • Figure 4-42: India - Pharmaceutical Market (Billion INR), 2006-07 to 2012-13
  • Figure 4-43: India - Pharmaceutical Imports (Billion INR), 2006-07 to 2012-13
  • Figure 4-44: India - Pharmaceutical Exports (Billion INR), 2006-07 to 2012-13
  • Figure 4-45: India - Forecast for Breakup of Domestic Pharmaceutical Market by Segment (%), 2010
  • Figure 4-46: China - Nominal GDP (Billion US$), 2007-2012
  • Figure 4-47: China - Consumer Price Index (%), 2007-2012
  • Figure 4-48: China - Foreign Direct Investment (Billion US$), 2005-2008
  • Figure 4-49: China - Population (Million), 2007-2012
  • Figure 4-50: China - Breakup of Population by Age Group (%), 2007-2012
  • Figure 4-51: China - Population in the Age Group of 65 Years & Above (Million), 2007-2012
  • Figure 4-52: China - Number of Deaths due to Leading Causes (‘000)
  • Figure 4-53: China - Breakup of Deaths by Various Causes (%), 2008
  • Figure 4-54: China - Per Head Healthcare Spending (US$), 2006-2012
  • Figure 4-55: China - Breakup of Healthcare Payment by Source (%), 2006
  • Figure 4-56: China - Pharmaceutical Market (Billion US$), 2007-2012
  • Figure 4-57: China - TCM Market (Billion CNY), 2005-2008
  • Figure 4-58: China - Pharmaceutical Purchase by Source (%)
  • Figure 4-59: China - Medicine & Health Product Imports (Billion US$), 2005-2007
  • Figure 4-60: China - Breakup of Medicine & Health Product Imports by Type (%), 2006
  • Figure 4-61: China - Medicine & Health Product Exports (Billion US$), 2005-2007
  • Figure 4-62: China - Breakup of Medicine & Health Product Exports by Type (%), 2006
  • Figure 4-63: China - Pharmaceutical Market by Type of Drug (%), 2007
  • Figure 4-64: Turkey - Nominal GDP (Billion US$), 2007-2012
  • Figure 4-65: Turkey - Consumer Price Index (%), 2007-2012
  • Figure 4-66: Turkey - Foreign Direct Investment (Billion US$), 2006-2008
  • Figure 4-67: Turkey - Population (Million), 2006-2012
  • Figure 4-68: Turkey - Breakup of Population by Age Group (%), 2006-2012
  • Figure 4-69: Turkey - Population in the Age Group of 65 Years & Above (Million), 2006-2012
  • Figure 4-70: Turkey - Number of Deaths due to Leading Causes (‘000)
  • Figure 4-71: Turkey - Breakup of Deaths by Various Causes (%), 2008
  • Figure 4-72: Turkey - Per Head Healthcare Spending (US$), 2006-2012
  • Figure 4-73: Turkey - Breakup of Healthcare Payment by Source (%)
  • Figure 4-74: Turkey - Pharmaceutical Market (Billion US$), 2007-2012
  • Figure 4-75: Turkey - Pharmaceutical Market (Million Boxes), 2006-2008
  • Figure 4-76: Turkey - Share of Imported & Domestically Manufactured Drugs in Pharmaceutical Market (2008)
  • Figure 4-77: Turkey - Pharmaceutical Exports (Million US$), 2006-2008
  • Figure 4-78: Turkey - Share of Branded & Generic Drugs in Pharmaceutical Market (2008)
  • Figure 4-79: Turkey - Share of Branded & Generic Drugs Sales Volume in Pharmaceutical Market (2008)
  • Figure 4-80: Mexico - Nominal GDP (Billion US$), 2007-2012
  • Figure 4-81: Mexico - Consumer Price Index (%), 2007-2012
  • Figure 4-82: Mexico - Foreign Direct Investment (Billion US$), 2006-2008
  • Figure 4-83: Mexico - Population (Million), 2006-2012
  • Figure 4-84: Mexico - Breakup of Population by Age Group (%), 2006-2012
  • Figure 4-85: Mexico - Population in the Age Group of 65 Years & Above (Million), 2006-2012
  • Figure 4-86: Mexico - Number of Deaths due to Leading Causes (‘000)
  • Figure 4-87: Mexico - Breakup of Deaths by Various Causes (%), 2008
  • Figure 4-88: Mexico - Per Head Healthcare Spending (US$), 2006-2012
  • Figure 4-89: Mexico - Breakup of Healthcare Payment by Source (%)
  • Figure 4-90: Mexico - Pharmaceutical Market (Billion US$), 2007-2012
  • Figure 4-91: Mexico - Pharmaceutical Imports (Billion US$), 2003 & 2007
  • Figure 4-92: Mexico - Pharmaceutical Exports (Billion US$), 2003, 2006 & 2007
  • Figure 4-93: Mexico - Share of Branded & Generic Drugs in Pharmaceutical Market (2008)
  • Figure 4-94: Mexico - Share of Top Players in Pharmaceutical Market (2007)
  • Figure 4-95: Indonesia - Nominal GDP (Billion US$), 2007-2012
  • Figure 4-96: Indonesia - Consumer Price Index (%), 2007-2012
  • Figure 4-97: Indonesia - Foreign Direct Investment (Billion US$), 2006-2008
  • Figure 4-98: Indonesia - Population (Million), 2007-2012
  • Figure 4-99: Indonesia - Breakup of Population by Age Group (%), 2007-2012
  • Figure 4-100: Indonesia - Population in the Age Group of 65 Years & Above (Million), 2007-2012
  • Figure 4-101: Indonesia - Number of Deaths due to Leading Causes (‘000), 2005
  • Figure 4-102: Indonesia - Breakup of Deaths by Various Causes (%), 2008
  • Figure 4-103: Indonesia - Per Head Healthcare Spending (US$), 2006-2012
  • Figure 4-104: Indonesia - Breakup of Healthcare Payment by Source (%), 2008
  • Figure 4-105: Indonesia - Pharmaceutical Market (Trillion Rp), 2007-2012
  • Figure 4-106: Indonesia - Share of OTC & Prescription Drugs in Pharmaceutical Market (2008)
  • Figure 4-107: Indonesia - Pharmaceutical Exports (Million US$) 2004-2007
  • Figure 4-108: Indonesia - Pharmaceutical Imports (Million US$) 2004-2007
  • Figure 4-109: Indonesia - Share of Branded & Generic Drugs in Pharmaceutical Market (2008)
  • Figure 4-110: Indonesia - Share of Top Players in Prescription Pharmaceutical Market (Q1 2009)
  • Figure 4-111: Indonesia - Share of Top Players in OTC Pharmaceutical Market (Q1 2009)
  • Figure 5-1: Global - Pharma Outsourcing Market by Segment (%), 2006
  • Figure 5-2: BRIC Countries - Medical Device Market (Million US$), 2006

List of Tables:

  • Table 2-1: Global - Pharmaceutical Market by Region (Billion US$), 2008
  • Table 3-1: E7 Countries - Disposable Income (Million US$), 2007 & 2012
  • Table 3-2: G7 Countries - Population (Million), 2007 & 2012
  • Table 3-3: E7 Countries - Population (Million), 2007 & 2012
  • Table 3-4: G7 Countries - Population in the Age Group of 65 Years & Above (Million), 2007 & 2012
  • Table 3-5: E7 Countries - Population in the Age Group of 65 Years & Above (Million), 2007 & 2012
  • Table 4-1: Brazil - Performance of Top 10 Players in Pharmaceutical Market (2006)
  • Table 4-2: Russia - Performance of Key Players in Pharmaceutical Market (2008)
  • Table 4-3: India - Performance of Drugs by Therapeutic Segment in Domestic Pharmaceutical Market
  • Table 4-4: India - Performance of Top 10 Pharmaceutical Players (2008)
  • Table 4-5: China - Performance of Drugs by Key Therapeutic Segment in Pharmaceutical Market (2005 & 2006)
  • Table 4-6: China - Performance of Key Players in Pharmaceutical Market (H1 2006 & H1 2007)
  • Table 4-7: Turkey - Performance of Key Therapy Areas in Pharmaceutical Market (2008)
  • Table 4-8: Turkey - Top 20 Pharmaceutical Players by Sales (Million US$), Jan-Sep 2007
  • Table 4-9: Turkey - Top 20 Pharmaceutical Players by Sales Volume (Million Units), Jan-Sep 2007
  • Table 4-10: Mexico - Performance of Therapy Areas in Retail Pharmaceutical Market (2006)
  • Table 5-1: India - Market for Various Chronic Diseases (Billion INR), 2006 & 2010
  • Table 5-2: India, China & Brazil - Vaccine Market (Million US$), 2006 & 2010
  • Table 7-1: GlaxoSmithKline plc - Strengths & Weaknesses
  • Table 7-2: Sanofi-Aventis - Strengths & Weaknesses
  • Table 7-3: Pfizer Inc - Strengths & Weaknesses
  • Table 7-4: Novartis - Strengths & Weaknesses
  • Table 7-5: AstraZeneca - Strengths & Weaknesses
Back to Top